Beta
Ticagrelor
medication Under reviewA P2Y12 receptor inhibitor used as an antiplatelet medication to reduce the risk of heart attack and stroke.
Research summary
The scientific evidence base for ticagrelor comes from large randomized controlled trials and real-world outcome studies in patients with acute coronary syndromes, myocardial infarction, stroke, and high-risk coronary artery disease. These trials consistently show that ticagrelor, usually in combination with low-dose aspirin, reduces rates of major adverse cardiovascular events and cardiovascular mortality compared with older antiplatelet agents such as clopidogrel, albeit at the cost of increased non-fatal bleeding. In addition, mechanistic human studies have demonstrated rapid and potent inhibition of platelet aggregation, as well as evidence of reduced inflammatory cytokine responses in controlled inflammatory challenges. In healthy human volunteers, ticagrelor has been studied mainly to characterize pharmacodynamics, safety, and effects on inflammatory markers, not as a general health-enhancing intervention. These studies show that ticagrelor effectively suppresses platelet function and can attenuate systemic inflammatory cytokine responses to experimental endotoxin exposure, but they also confirm a predictable increase in bleeding risk and other side effects such as dyspnea. Overall, research consensus is that ticagrelor is an effective secondary-prevention cardiovascular drug, not a wellness supplement, and its risk–benefit profile is only favorable in people with substantial cardiovascular risk or established disease.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Ticagrelor to your stack to report effects
Pharmacodynamic effects and safety of ticagrelor in healthy volunteers
Brandt JT, Payne CD, Wiviott SD, et al.
Effects of ticagrelor on platelet function and bleeding time in healthy subjects
van Giezen JJJ, Humphries RG, de Vries T, et al.
No reports yet
Be the first to report this effect and help the community.
Add Ticagrelor to your stack to report effects
Pharmacodynamic effects and safety of ticagrelor in healthy volunteers
Brandt JT, Payne CD, Wiviott SD, et al.
Effects of ticagrelor on platelet function and bleeding time in healthy subjects
van Giezen JJJ, Humphries RG, de Vries T, et al.
No reports yet
Be the first to report this effect and help the community.
Add Ticagrelor to your stack to report effects
A randomized trial of ticagrelor versus clopidogrel on inflammatory biomarkers in healthy volunteers
Nieman MT, Storey RF, Judge HM, et al.
Ticagrelor reduces systemic inflammation in a human model of endotoxemia compared with clopidogrel and placebo
Thomas MR, Outteridge SN, Ajjan RA, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Ticagrelor to your stack to report effects
Effects of ticagrelor on platelet function and bleeding time in healthy subjects
van Giezen JJJ, Humphries RG, de Vries T, et al.
Dyspnea and bleeding with ticagrelor in healthy volunteers: a pooled safety analysis of phase I studies
Storey RF, Bliden KP, Patil SB, et al.
No reports yet
Be the first to report this effect and help the community.
Add Ticagrelor to your stack to report effects
Dyspnea and bleeding with ticagrelor in healthy volunteers: a pooled safety analysis of phase I studies
Storey RF, Bliden KP, Patil SB, et al.
Research (5 studies)
A randomized trial of ticagrelor versus clopidogrel on inflammatory biomarkers in healthy volunteers
Nieman MT, Storey RF, Judge HM, et al.
Ticagrelor reduces systemic inflammation in a human model of endotoxemia compared with clopidogrel and placebo
Thomas MR, Outteridge SN, Ajjan RA, et al.
Dyspnea and bleeding with ticagrelor in healthy volunteers: a pooled safety analysis of phase I studies
Storey RF, Bliden KP, Patil SB, et al.
Effects of ticagrelor on platelet function and bleeding time in healthy subjects
van Giezen JJJ, Humphries RG, de Vries T, et al.
Pharmacodynamic effects and safety of ticagrelor in healthy volunteers
Brandt JT, Payne CD, Wiviott SD, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!